Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs
Despite its standing as pharma’s biggest cancer player, Roche has mostly stood pat on next-gen cell therapies that its competitors have gobbled up with gusto. Ready to finally make a splash of its own, Roche has inked a major deal to dive into the future.
Roche’s Genentech has signed a deal worth $150 million upfront and a total value of more than $3 billion to partner with Adaptimmune on off-the-shelf T cell therapies that marks the cancer giant’s first significant pipeline pivot into next-gen oncology drugs, the partners said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.